Meningococcal immunology

Immunol Allergy Clin North Am. 2003 Nov;23(4):769-86. doi: 10.1016/s0889-8561(03)00092-4.

Abstract

There is a major need for an effective vaccine against serogroup B disease. The long-term efficacy of the serogroups A, C, Y and W135 conjugate vaccines and the need for booster vaccines has to be determined, as does the effect of changing epidemiology in the United States and worldwide. Control of serogroup A disease in sub-Saharan Africa is a major challenge.

Publication types

  • Review

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Child
  • Child, Preschool
  • Humans
  • Infant
  • Meningitis, Meningococcal / epidemiology
  • Meningitis, Meningococcal / immunology*
  • Meningitis, Meningococcal / prevention & control*
  • Meningitis, Meningococcal / virology
  • Meningococcal Vaccines / administration & dosage*
  • Meningococcal Vaccines / immunology
  • Neisseria meningitidis / virology*
  • United States / epidemiology

Substances

  • Meningococcal Vaccines